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Prevention of influenza transmission and containment of epidemics and
pandemics require effective strategies that can be efficiently and easily
addressed to the whole population. Annual vaccination is undoubtedly the
most effective way to provide protection against influenza infection. Num-
bers of vaccines are actually available for yearly immunisation. However, the
continuous increasing demand for rapidly available vaccine doses for immuni-
sation of a larger proportion of population represents the stimulus for study
and development of more efficient vaccine production technologies, which
can guarantee reduction of vaccine manufacture times and better compliance
by availability of easier routes of administration. New perspectives in influ-
enza vaccination technology are making their way in the future panorama
of influenza prevention strategies.
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1. Commentary
Effective prevention of infectious diseases transmission has always represented a
challenge for scientists and public health authorities. Recently, the worldwide spread
of the novel swine influenza H1N1 pandemic in 2009 highlighted the urgent need
for rapid development of infectious diseases containment strategies for protecting
population and preventing increasing morbidity and mortality.
Influenza is a highly infectious respiratory disease for which the World Health
Organisation (WHO) has reported annually from three to five million cases [1].
Although generally benign, influenza is considered responsible for a number of
complications in patients with chronic underlying diseases which result in increasing
direct and indirect costs for the affected subjects and, globally, for the whole society.
Strategies for mitigation and containment of influenza epidemics can rely on
well-known effective non-pharmaceutical and pharmaceutical interventions, such
as individual hygiene, wearing face masks, quarantine, social distancing and admin-
istration of antiviral drugs and vaccines. Influenza vaccination represents actually
the most effective strategy for preventing the disease and its eventually associated
complications. For the 2010 -- 2011 influenza season, the centers for Disease Con-
trol (CDC) suggested universal vaccination for all healthy and at risk subjects from
6 months of age onwards. Traditional trivalent inactivated influenza vaccines are
largely available and, recently, a live-attenuated intranasally administered influenza
vaccine has been licensed in the USA for healthy non-pregnant subjects from 2 to
49 years of age. Recent studies demonstrated a better immunogenicity of this vac-
cine particularly in children; however, safety data in the paediatric population are
already contrasting [2].
Numbers of new influenza vaccines are being studied and developed by exploring
either new production technologies or new, easier routes of administration.
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The first challenge is the one associated with circumventing
the problems of egg-based vaccine manufacture, characterised
by poor flexibility and long-lasting production times, which
cannot effectively respond to the eventually increasing
demand for rapidly available vaccine doses in case of a
new pandemic.
Encouraging results are being observed with studies on cell-
based vaccines. The use of mammalian or insect cell-culture
lines has numerous advantages: shortening of production
times, easier production of avian strain influenza vaccines
which generally poorly grow in egg substrates, absence of
sterility issues and improved immunogenicity because of
better antigen presentation. Madin Darbin Canine Kidney
(MDCK) cells, VERO cells, from African green monkey kid-
ney cells and PER C.6 from fetal retinal human cells are
mammalian cell lines used in new influenza vaccination tech-
nologies. The MDCK cell line has been extensively studied
and a numbers of experimental MDCK-grown influenza inac-
tivated vaccines have been reported to have a good immuno-
genicity, at least comparable to the traditional vaccines, and
a reassuring safety profile, with similar tolerability to the
egg-grown vaccines [3,4]. A MDCK live cold-adapted
attenuated influenza vaccine has been recently evaluated,
too [5].
VERO-cell-based influenza vaccines were demonstrated to
be highly immunogenic, with good humoral and cellular
immune responses, with the latter being even more efficient
than that of traditional inactivated vaccines [6].
As regards the PER C.6 cell-line, a Phase III study on adult
subjects is being performed by Crucell and an application for
license of the new vaccine is expected in 2014 [7].
Another promising alternative egg-independent vaccine
production strategy is the one of viral vectors. Viral vectors
(adenovirus, poxvirus, alphavirus) have been extensively stud-
ied for being used in influenza antigen presentation; however,
they have not been initially considered for vaccine production
because of safety concerns. Subsequent preclinical and clinical
trials have later demonstrated that genetically modified viral
vectors cannot multiply but continue presenting antigens
effectively, so that they can be safely used for vaccine produc-
tion. A preclinical study on animal models showed that an
adenoviral-vector-based, adjuvant- and egg-independent pan-
demic influenza vaccine (HAd) is able to efficiently present
influenza virus antigens and elicit good and long-lasting
humoral and cellular responses against H5N1 strains [8].
Moreover, the adenovirus-vectored strategy, as intranasal or
epicutaneous administered vaccine, has been evaluated in
24 healthy adult subjects, proving to be both immunogenic
and safe [9].
Non-replicating virus-like particles (VLPs), resulting from
a self-assembly process in a viral life cycle, are other candidates
for new influenza vaccines. VLPs can be produced both from
enveloped and non-enveloped viruses. Because of their
non-infectious nature, VLP-based vaccines can be safely
administered even in high-risk populations. A good
immunogenicity of this vaccine candidate has been observed
in animal models; in humans, preliminary results from a run-
ning clinical trial showed that the vaccine could elicit a good
immune response against H5N1 strains without safety
concerns [10].
DNA technology was first used in influenza vaccine manu-
facture in 1993. A number of subsequent influenza vaccine
preclinical trials in animal models suggested the possibility
of eliciting both humoral and T cell-based immune responses.
However, despite these encouraging preliminary results, the
first human DNA-based intramuscularly administered influ-
enza vaccine study showed no protective immune response.
Subsequent human studies demonstrated positive results and
a very recent Phase I clinical trial in 103 healthy adult subjects
immunised with an adjuvanted DNA-based H5N1 intra-
dermally administered influenza vaccine showed a good
immunogenicity and safety [11].
Antigenic drift of viral membrane proteins haemoaggluiti-
nin (HA) and neuroaminidase (NA) is the reason for the
annual update of influenza vaccine formulations. Highly con-
served viral proteins, such as membrane protein M2e and
nucleoprotein (NP), represent new molecular targets for influ-
enza vaccine production which have been evaluated both in
preclinical and clinical trials with promising initial results.
A good immunogenicity against highly pathogenic viruses
has been observed with the combination of the two viral
proteins [12].
Several studies of new vaccine administration routes have
been recently published. Making vaccine administration easier
is an important goal in a successful influenza prevention strat-
egy. Other administration routes apart from intramuscular
and deep-subcutaneous ones are intranasal, pulmonary, epi-
dermal and oral. New anatomical administration sites offer
in fact some important advantages if compared with the tradi-
tional ones: easier conservation and distribution of vaccines,
reduction of adverse effect rates, in particular those associated
with needle use, a better mucosal immune response through a
local IgA-mediated stimulus, increasing patient compliance
and cost savings.
A liquid intranasally administered influenza vaccine has
been already licensed in the USA however a new dry-
powder intranasal formulation is being evaluated. Powder
formulation vaccines show better stability and sterility
and can be stored at room or even somewhat higher tem-
peratures, without necessity for cold chain facilities and so
much easier conservation. Moreover, the stability of dry-
powder formulations results in an increase of vaccine
shelf-life, facilitating stockpiling of readily available vaccine
doses in case of new pandemics. All these features make
the new powder intranasally administered vaccine one
of the best candidates for mass influenza vaccination.
A preclinical study on rats demonstrated the generation of
strong nasal mucosal and systemic immune response by
intranasal delivery of a dry-powder-formulated influenza
vaccine [13].
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Pulmonary delivery of powder-formulated influenza vac-
cines can represent an alternative to intranasal administration.
Lungs have a much larger highly vascularized absorptive sur-
face area, contain mucosa-associated lymphoid tissue and an
abundance of macrophages and dendritic cells which act as
local antigen-presenting cells. Dry-powder formulations for
pulmonary delivery are designed as micrometer size particles
which can reach the lower airways, smaller bronchioles and
alveoli, and induce both a local and systemic immunity.
A pulmonary-delivered spray-freeze-dried influenza subunit
vaccine has been administered in mice demonstrating a good
mucosal, humoral and cell-mediated immune response which
proved to be superior both to conventional intramuscular and
liquid aerosolised administration routes [14].
The epidermis represent another promising anatomical tar-
get for influenza vaccine delivery. A great portion of the
immune system has its localisation in the cutis: Langerhans
cells, local antigen-presenting cells, can effectively stimulate
a CD4 and CD8 T-cell-mediated immune response and
favour antigen presentation by production of local stimulating
cytokines. A number of epidermal delivery methods are being
evaluated. Jet injectors for powder formulations have been
developed to obtain high speed acceleration of 20 -- 70 µm
particles which can penetrate the stratum corneum and effec-
tively reach the epidermis. In a Phase I clinical trial, epidermal
powder influenza immunisation in humans using a jet injector
device resulted in humoral immune response with a good
safety profile [15].
The ultimate nanotechnologies have been recently applied
to manufacture of microscopic and minimally invasive devices
for epidermal delivery of influenza vaccines. Microneedle
devices are being developed for effective and pain-free
administration of vaccines across the skin barrier layer.
Microneedles allowed delivery of vaccines in the underlying
skin compartments inducing local and, through cutaneous
circulation, systemic effects. Recent studies demonstrated
that the delivery of vaccine by microneedle provides
immunological responses at least equal if not superior to the
intramuscular injection [16,17].
Functional miniaturisation of vaccine delivery devices has
been recently achieved with development of a densely
packed dissolving microprojection array, Nanopatch. This
consists of highly dense silicon projections which are coated
with vaccines in dry form and applied to the skin: stratum
corneum is crossed and vaccine is directly delivered to the
immunologically sensitive cells in the skin [18].
Oral administration is another stimulating possibility for
influenza immunisation. It is a simple, safe, pain-free, non-
invasive and cheap administration route. Oral vaccination
can elicit an IgA-mediated mucosal immune response in the
respiratory tract which protects the subject at the port of entry
of infection and might offer broader protection against anti-
genically drifted influenza strains, too [19]. Unfortunately
oral immunisation resulted in scarce IgG responses and stud-
ies are needed to evaluate if an IgA immune response could
alone provide adequate protection against influenza infection.
Lastly, eye mucosa represent a new anatomical target and a
fascinating alternative vaccine administration route. A first
study in animal models demonstrated effective virus-specific
humoral mucosal and systemic responses after eyedrop
influenza vaccination [20].
Declaration of interest
The authors state no conflict of interest and have received no
payment in preparation of this manuscript.
Zuccotti & Fabiano























































1. Influenza (seasonal). World health
Organization. Fact sheet No 211. Geneva,
Switzerland: WHO, 2009. Available
from: www.who.int/mediacentre/
factsheets/fs211/en/index.html
[Last accessed 11 November 2010]
2. Belshe RB, Ambrose CS, Yi T. Safety
and efficacy of live attenuated influenza
vaccine in children 2-7 years of age.
Vaccine 2008;26(Suppl 4):D10-16
3. Palache AM, Scheepers HSJ, de Regt V,
et al. Safety, reactogenicity and
immunogenicity of Madin Darbin
Canine Kidney cell-derived inactivated
influenza subunit vaccine: a meta-analysis
of clinical studies. Dev Biol Stand
1999;98:115-25
4. Halperin SA, Smith B, Mabrouk T,
et al. Safety and immunogenicity of a
trivalent, inactivated, mammalian cell
culture-derived influenza vaccine in
healthy adults, seniors, and children.
Vaccine 2002;20:1240-7
5. Ghendon YZ, Markushin SG,
Akopova II, et al. Development of cell
culture (MDCK) live cold-adapted (CA)
attenuated influenza vaccine. Vaccine
2005;23:4678-84
6. Bruhl P, Kerschbaum A, Kistner O, et al.
Humoral and cell-mediated immunity to
vero cell-derived influenza vaccine.
Vaccine 2000;19:1149-58
7. Influenza -- Seasonal influenza Vaccine.
Leiden, The Netherlands: Crucell,
2009. Available from: http://www.crucell.
com/R_and_D-Clinical_Development-
Epidemic_Influenza_Vaccine
[Last accessed 11 November 2010]
8. Hoelscher MA, Jayashankar L, Garg S,
et al. New pre-pandemic influenza
vaccine: an egg- and
adjuvant-independent human adenoviral
vector strategy inducing long lasting
protective immune responses in mice.
Clin Pharmacol Ther 2007;82:665-71
9. Van Kampen KR, Shi Z, Gao P, et al.
Safety and immunogenicity of
adenovirus-vectored nasal and
epicutaneous influenza vaccines in
humans. Vaccine 2005;23:1029-36
10. Richardson T. Novavax Announces
Favourable Interim Results from Human
Clinical Trial for its Pandemic Influenza
Vaccine Program. Rockville, MD:
Novavax, December
2007. Available from: http://www.
novavax.com/download/releases/
pandemicinterimresultsPR%20FO.pdf
[Last accessed 11 November 2010]
11. Smith LR, Wloch MK, Ye M, et al.
Phase 1 clinical trials of the safety and
immunogenicity of adjuvanted plasmid
DNA vaccines encoding influenza A virus
H5 haemoaggluitinin. Vaccine
2010;16:2565-72
12. Price GE, Soboleski MR, Lo CY, et al.
Vaccination focusing immunity on
conserved antigens protects mice and
ferrets against virulent H1N1 and
H1N5 influenza A viruses. Vaccine
2009;27:6512-21
13. Huang J, Garmise RJ, Crowdre TM,
et al. A novel dry powder influenza
vaccine and intranasal delivery
technology: induction of systemic and
mucosal immune responses in rats.
Vaccine 2004;23:794-801
14. Amorij JP, Saluja V, Petersen AH,
et al. Pulmonary delivery of an
inulin-stabilized influenza subunit vaccine
prepared by spray-freeze drying induces
systemic, mucosal humoral as well as
cell-mediated immune responses in
BALB/c mice. Vaccine 2007;25:8707-17
15. Chen D, Burger M, Chu Q, et al.
Epidermal powder immunization: cellular
and molecular mechanisms for enhancing
vaccine immunogenicity. Virus Res
2004;103:147-53
16. Kim YC, Quan FS, Yoo DG, et al.
Improved influenza vaccination in the
skin using vaccine coated microneedles.
Vaccine 2009;27:6932-8
17. Pearton M, Kang SM, Song JM, et al.
Vaccine 2010;28:6104-13
18. Raphael AP, Prow TW, Crichton ML,
et al. Targeted, needle-free vaccinations




19. Tumpey TM, Renshaw M, Clements JD,
et al. Mucosal delivery of inactivated
influenza vaccine induces
B-cell-dependent heterosubtypic
cross-protection against lethal influenza
A H5N1 virus infection. J Virol
2001;75:5141-50
20. Seo KY, Han SJ, Cha HR, et al. Eye
mucosa: an efficient vaccine delivery
route for inducing protective immunity.
J Immunol 2010;185:3610-19
Affiliation





Universita` degli Studi di Milano,
Via GB Grassi, 74, 20157, Milan Italy
Tel: +39 0239042253; Fax: +39 0239042254
E-mail: gianvincenzo.zuccotti@unimi.it
Strategies for preventing influenza
4 Expert Opin. Biol. Ther. (2011) 11(1)
Ex
pe
rt 
O
pi
n.
 B
io
l. 
Th
er
. D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
93
.3
4.
17
7.
8 
on
 1
2/
07
/1
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
